HomeAI · summaries
Storia in 4 fonti
Lilly offers up to $1.9B in new drug discovery deal with Abbisko
Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
- ·
forbes.com
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Strategic research collaboration and license agreement is worth up to $1.9 billion to Abbisko
- ·
morningstar.com
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
- ·
Lilly offers up to $1.9B in new drug discovery deal with Abbisko
Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion.
- ·
benzinga.com
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)
Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.